AbbVie vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?

Eli Lilly’s metabolic therapies drove 45% revenue growth, but its valuation premium demands scrutiny against AbbVie’s defensive dividend appeal.

This post was originally published on this site.

About the Author

Staff Writer

Written by a Staff Writer at this publication, this article reflects the work of our editorial team. Our staff writers cover topics locally and nationally to keep you informed on the top stories of our time.

About the Author

Staff Writer

Leave a Reply Cancel Reply

Popular Posts

South Carolina police officer killed in park shooting during domestic dispute

Warsh, After Talking Tough on Inflation, Faces a ‘No-Win Situation’ on Rates

Trump cannot deport students for criticizing Israel, federal judge rules

Far-right critic of US immigration Milo Yiannopoulos deported for being in US illegally

New U.S. sanctions will hit ordinary Iranians hard. That may be the whole point as the crashing economy stirs fresh protests

Nepal floods latest: Rescue efforts enter fifth day with more than 2,400 missing after flash flood